Share this page!

Alejandro Da Lozzo, MD MSc(c) Profile picture
Twitter logo
2 Oct, 6 tweets, 2 min read
Mujer 54 años. No tabaquista. Padre fallecido de cáncer de pulmón. Rx de rutina con nódulo pulmonar. TC lo confirma. Nódulo pulmonar en lóbulo superior derecho hipercaptante en PET/TC con grupos ganglionares N1 (10R) y N2 (4R) con hipercaptación. No tabaquista. #ClinicalChallenge ImageImageImageImage
¿Cómo seguiría con este paciente?
Relájate @__yamila__ y votá. ¡Vos sabés! Sos experta en la materia. Soltá al gasista.
A votar, hagan RT. Ya sale la respuesta. Y les sorprenderá.
Salió resolución del #ClinicalChallenge

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Alejandro Da Lozzo, MD MSc(c)

Alejandro Da Lozzo, MD MSc(c) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @adalozzo

Alejandro Da Lozzo, MD MSc(c) Profile picture
3 Oct
Acá va la resolución del caso #ClinicalChallenge Veamos una por una las opciones. RT @SToracica @aacirugia @AAMRargentina
1) Hay que convencer al paciente que no tiene nada, hay que convencer al juez que ante un diagnóstico positivo no se hizo nada. No parece ser una sabia decisión. Siempre ante un hallazgo positivo, se debe tomar una conducta. Si no, para qué pedimos el estudio.
2) La biopsia percutánea tiene sensibilidad (S) 82-99%, especificidad (E) 86-100% y eficacia 64-97% para el diagnóstico de malignidad. Sin embargo, un diagnóstico definitivo de benignidad sólo se da en el 20-50% bit.ly/3mirHV0
Read 13 tweets
Alejandro Da Lozzo, MD MSc(c) Profile picture
2 Oct
-No me digas que están haciendo una Fase 3, sin decirle a la población.
-Sí
-Te dije que no me digas.
#ElPeorGobiernoDeLaHistoria

La OMS no lo avala who.int/publications/i…
thelancet.com/journals/lanin… inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3–17 years. BBIBP-CorV also elicited robust humoral responses against SARS-CoV-2 infection after two doses.
Our findings support the use of a 4 μg dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @adalozzo has new unrolls!

Check out other threads from @adalozzo!

Read all threads by @adalozzo

:(